A Five-Gene Prognostic Nomogram Predicting Disease-Free Survival of Differentiated Thyroid Cancer

Table 2

Clinical baseline features of DTC patients in the training and testing datasets.

Clinical features	Training dataset; 305		Testing dataset; 128
		%		%
Cancer type, (%)
PTC	247	80.98	104	81.25
FTC	58	19.02	24	18.75
Age, (%)
≤55	223	73.11	88	68.75
>55	82	26.89	40	31.25
Gender, (%)
Male	79	25.90	39	30.47
Female	226	74.10	89	69.53
Disease-free survival (year) ()
Recurrence, (%)
Yes	31	10.16	13	10.16
No	274	89.84	115	89.84
Tumor size, (%)
≤2 cm	100	32.79	28	21.88
>2 cm	205	67.21	100	78.12
N, (%)
N0	153	50.16	70	54.69
N1	39	12.79	16	12.50
N1a	65	21.31	20	15.63
N1b	48	15.74	22	17.18
M, (%)
M0	182	59.67	79	61.72
M1	5	1.64	2	1.56
MX	118	38.69	47	36.72
Anatomic site, (%)
Bilateral	55	18.03	28	21.88
Isthmus	13	4.26	6	4.69
Unilateral	237	77.71	94	73.43
Stage, (%)
Stage I	177	58.03	70	54.69
Stage II	28	9.18	14	10.94
Stage III	68	22.30	27	21.09
Stage IV	32	10.49	17	13.28
ATA risk stratification, (%)
High risk	14	4.59	8	6.25
Intermediate risk	184	60.33	67	52.34
Low risk	107	35.08	53	41.41
ETA risk stratification, (%)
High risk	198	64.92	75	58.59
Low risk	100	32.79	48	37.50
Very low risk	7	2.29	5	3.91